Gilead Sciences (NASDAQ:GILD) Hits New 1-Year High - What's Next?

Shares of Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) reached a new 52-week high on Monday . The company traded as high as $99.37 and last traded at $99.24, with a volume of 1879395 shares. The stock had previously closed at $97.20.

Wall Street Analyst Weigh In

GILD has been the subject of several recent research reports. The Goldman Sachs Group upped their price target on Gilead Sciences from $74.00 to $84.00 and gave the company a "neutral" rating in a report on Thursday, November 7th. Mizuho upped their target price on Gilead Sciences from $90.00 to $100.00 and gave the company an "outperform" rating in a research note on Thursday, November 21st. BMO Capital Markets boosted their price target on shares of Gilead Sciences from $94.00 to $102.00 and gave the company an "outperform" rating in a report on Thursday, November 7th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $80.00 price objective on shares of Gilead Sciences in a report on Wednesday, December 11th. Finally, Piper Sandler increased their price target on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th. Eleven analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences currently has an average rating of "Moderate Buy" and an average target price of $98.39.

Gilead Sciences Price Performance

The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The stock's 50-day moving average price is $92.86 and its 200-day moving average price is $86.41. The company has a market capitalization of $122.18 billion, a price-to-earnings ratio of 1,089.33, a price-to-earnings-growth ratio of 1.37 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business's revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.29 EPS. Equities research analysts anticipate that Gilead Sciences, Inc. will post 4.34 earnings per share for the current year.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 248,645 shares of the firm's stock in a transaction on Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the transaction, the chief financial officer now directly owns 138,919 shares in the company, valued at $12,886,126.44. This trade represents a 64.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jeffrey Bluestone sold 6,788 shares of the company's stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the sale, the director now owns 8,920 shares of the company's stock, valued at $815,198.80. This represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 572,824 shares of company stock valued at $53,611,715 over the last 90 days. 0.29% of the stock is owned by company insiders.

Hedge Funds Weigh In On Gilead Sciences

Several institutional investors have recently modified their holdings of the stock. Algert Global LLC acquired a new stake in Gilead Sciences in the second quarter worth $254,000. AMF Tjanstepension AB raised its stake in Gilead Sciences by 14.7% during the 3rd quarter. AMF Tjanstepension AB now owns 400,819 shares of the biopharmaceutical company's stock worth $33,645,000 after buying an additional 51,390 shares during the period. Czech National Bank lifted its holdings in Gilead Sciences by 6.8% during the third quarter. Czech National Bank now owns 253,618 shares of the biopharmaceutical company's stock worth $21,263,000 after acquiring an additional 16,209 shares in the last quarter. Aprio Wealth Management LLC acquired a new position in Gilead Sciences in the third quarter valued at about $290,000. Finally, Atomi Financial Group Inc. increased its holdings in shares of Gilead Sciences by 36.0% in the third quarter. Atomi Financial Group Inc. now owns 6,081 shares of the biopharmaceutical company's stock worth $510,000 after acquiring an additional 1,610 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.